A new role in hemostasis for the adhesion receptor P-selectin

Trends in Molecular Medicine

Volumn 10, Issue 4, 2004, Pages 179-186

  Cambien, Beatrice ^a   Wagner, Denisa D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CD11B ANTIGEN; CELL ADHESION MOLECULE; FIBRINOGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; P SELECTIN GLYCOPROTEIN LIGAND 1 ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1 IMMUNOGLOBULIN; P SELECTIN MONOCLONAL ANTIBODY; PADGEM PROTEIN; PROCOAGULANT; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTERY OCCLUSION; ARTERY THROMBOSIS; BABOON; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR DISEASE; CAT; DACRON IMPLANT; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DOG; ENDOCARDITIS; FIBRIN DEPOSITION; FIBRIN FORMATION; GENE EXPRESSION; GLOMERULONEPHRITIS; HEART INFARCTION; HEMOPHILIA A; HEMOSTASIS; HYPERCOAGULABILITY; INFLAMMATION; LEUKOCYTE; NONHUMAN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE; THROMBOCYTE DISORDER; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS; WEIBEL PALADE BODY; WILD TYPE;

ANIMALS; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; CELL ADHESION; FIBRIN; HUMANS; INFLAMMATION; LEUKOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; P-SELECTIN; PHENOTYPE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; THROMBOPLASTIN; THROMBOSIS;

CANIS FAMILIARIS; FELIS CATUS; PAPIO HAMADRYAS; PURPURA;

EID: 1642603431     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.02.007     Document Type: Review

References (83)

1. Ley K. The role of selectins in inflammation and disease. Trends Mol. Med. 9:2003;263-268.
2. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 86:2001;746-756.
3. Larsen E., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 59:1989;305-312.
4. Lawrence M.B., Springer T.A. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 65:1991;859-873.
5. Frenette P.S., et al. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 91:1998;1318-1324.
6. Dunlop L.C., et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J. Exp. Med. 175:1992;1147-1150.
7. Hartwell D.W., et al. Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J. Cell Biol. 143:1998;1129-1141.
8. Johnston G.I., et al. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J. Biol. Chem. 265:1990;21381-21385.
9. Ishiwata N., et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J. Biol. Chem. 269:1994;23708-23715.
10. Berger G., et al. P-Selectin and platelet clearance. Blood. 92:1998;4446-4452.
11. Moore K.L., et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J. Cell Biol. 128:1995;661-671.
12. Norman K.E., et al. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. Blood. 86:1995;4417-4421.
13. Frenette P.S., et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J. Exp. Med. 191:2000;1413-1422.
14. Mayadas T.N., et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 74:1993;541-554.
15. Wagner R. Erlauterungstalfeln zur Physiologie und Entwicklungsgescgichte. 1839;Leopold Voss.
16. Frenette P.S., et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7450-7454.
17. Romo G.M., et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J. Exp. Med. 190:1999;803-814.
18. Sporn L.A., et al. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 46:1986;185-190.
19. Padilla, A. et al. (2003) P-selectin anchors newly released ultra-large von Willebrand factor multimers to the endothelial cell surface. Blood [Epub ahead of print].
20. Michelson A.D., et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 104:2001;1533-1537.
21. Schober A., et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 106:2002;1523-1529.
22. Wagner D.D., Burger P.C. Platelets in inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 23:2003;2131-2137.
23. Massberg S., et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood. 92:1998;507-515.
24. Ishikawa M., et al. Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke. 34:2003;1777-1782.
25. Smyth S.S., et al. β(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 103:2001;2501-2507.
26. Ni H., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest. 106:2000;385-392.
27. Ni H., et al. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood. 102:2003;3609-3614.
28. Palabrica T., et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 359:1992;848-851.
29. Subramaniam M., et al. Defects in hemostasis in P-selectin-deficient mice. Blood. 87:1996;1238-1242.
30. Andre P., et al. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13835-13840.
31. Disdier M., et al. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol. Biol. Cell. 3:1992;309-321.
32. Sullivan V.V., et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J. Surg. Res. 109:2003;1-7.
33. Myers D.D., et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J. Vasc. Surg. 38:2003;1075-1089.
34. Nemerson Y. Tissue factor and hemostasis. Blood. 71:1988;1-8.
35. Niemetz J. Coagulant activity of leukocytes. Tissue factor activity. J. Clin. Invest. 51:1972;307-313.
36. Celi A., et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8767-8771.
37. Bogdanov V.Y., et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat. Med. 9:2003;458-462.
38. Rauch U., Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc. Med. 10:2000;139-143.
39. Giesen P.L., et al. Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2311-2315.
40. Hrachovinova I., et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. 9:2003;1020-1025.
41. Freyssinet J.M. Cellular microparticles: what are they bad or good for? J. Thromb. Haemost. 1:2003;1655-1662.
42. Toti F., et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 87:1996;1409-1415.
43. Weiss H.J. Scott syndrome: a disorder of platelet coagulant activity. Semin. Hematol. 31:1994;312-319.
44. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82:1999;165-174.
45. VanWijk M.J., et al. Microparticles in cardiovascular diseases. Cardiovasc. Res. 59:2003;277-287.
46. Mesri M., Altieri D.C. Endothelial cell activation by leukocyte microparticles. J. Immunol. 161:1998;4382-4387.
47. Mesri M., Altieri D.C. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J. Biol. Chem. 274:1999;23111-23118.
48. Sabatier F., et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 99:2002;3962-3970.
49. Weerheim A.M., et al. Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal. Biochem. 302:2002;191-198.
50. Weyrich A.S., et al. Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. Circulation. 106:2002;1433-1435.
51. Falati S., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197:2003;1585-1598.
52. Falati S., et al. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8:2002;1175-1181.
53. Furie, B. and Furie, B.C. (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol. Med. 10, 171-178, preceding article in this issue.
54. Simon D.I., et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J. Exp. Med. 192:2000;193-204.
55. Altieri D.C., et al. The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion. J. Biol. Chem. 268:1993;1847-1853.
56. Engelmann B., et al. Intravascular tissue factor pathway - a model for rapid initiation of coagulation within the blood vessel. Thromb. Haemost. 89:2003;3-8.
57. Michelson A.D., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11877-11882.
58. Burger P.C., Wagner D.D. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 101:2003;2661-2666.
59. Chong B.H., et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 83:1994;1535-1541.
60. Wu G., et al. Detection of plasma alpha-granule membrane protein GMP-140 using radiolabeled monoclonal antibodies in thrombotic diseases. Haemostasis. 23:1993;121-128.
61. Blann A.D., et al. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb. Haemost. 74:1995;626-630.
62. Smith A., et al. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb. Haemost. 82:1999;1593-1599.
63. Ikeda H., et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 92:1995;1693-1696.
64. Tsakiris D.A., et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis. 142:1999;193-200.
65. Ikeda H., et al. Soluble form of P-selectin in patients with acute myocardial infarction. Coron. Artery Dis. 5:1994;515-518.
66. Korkmaz S., et al. Increased levels of soluble adhesion molecules, E-selectin and P-selectin, in patients with infective endocarditis and embolic events. Eur. Heart J. 22:2001;874-878.
67. Ridker P.M., et al. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 103:2001;491-495.
68. Hillis G.S., et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am. Heart J. 143:2002;235-241.
69. Salzman E.W., Hirsh J. The epidemiology, pathogenesis, and natural history if venous thrombus. Colman R.W., et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1994;1275-1289 Lippincott Williams & Wilkins.
70. McEver R.P. P-selectin and PSGL-1: exploiting connections between inflammation and venous thrombosis. Thromb. Haemost. 87:2002;364-365.
71. Esmon C.T. Role of coagulation inhibitors in inflammation. Thromb. Haemost. 86:2001;51-56.
72. Myers D., et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb. Haemost. 87:2002;374-382.
73. Kumar A., et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation. 99:1999;1363-1369.
74. Mannucci P.M., Tuddenham E.G. The hemophilias - from royal genes to gene therapy. N. Engl. J. Med. 344:2001;1773-1779.
75. Toombs C.F., et al. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J. Pharmacol. Exp. Ther. 275:1995;941-949.
76. Ueyama T., et al. Effects of monoclonal antibody to P-selectin and analogue of sialyl Lewis X on cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation. 95:1997;1554-1559.
77. Downing L.J., et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J. Vasc. Surg. 25:1997;816-828.
78. Wakefield T.W., et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J. Vasc. Surg. 31:2000;309-324.
79. Myers D.D. Jr, et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb. Haemost. 85:2001;423-429.
80. Eppihimer M.J., Schaub R.G. P-Selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler. Thromb. Vasc. Biol. 20:2000;2483-2488.
81. Myers D.D. Jr, et al. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J. Vasc. Surg. 36:2002;928-938.
82. Connolly E.S. Jr, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ. Res. 81:1997;304-310.
83. Ito I., et al. Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. Am. J. Kidney Dis. 38:2001;265-273.